BioCryst Pharmaceuticals, Inc. - Common Stock - Nakit Akışı (NASDAQ:BCRX)

Financials

İşletme faaliyetlerinden elde edilen nakit -137.22 M-142.16 M-161.85 M-95.14 M-52.02 M347.37 M 313.1 M Yatırım faaliyetlerinden elde edilen nakit -6.86 M15.8 M-128.24 M-131.5 M52.59 M-13.69 M -309.44 M Finansman faaliyetlerinden elde edilen nakit 302.7 M359.67 M88.03 M32.48 M-5.76 M-349.93 M 62.09 M Serbest nakit akışı -137.73 M-144.54 M-163.2 M-97.31 M-53.14 M344.9 M 310.37 M

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

BCRX

Financials

BioCryst Pharmaceuticals, Inc. - Common Stock

Haberler

BioCryst’in 2026 1Ç sunumu: HAE stratejisi 1,8 milyar dolar hedefliyor

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings - BioCryst Pharma (NASDAQ:BCRX

Citizens, Orladeyo büyüme görünümüyle BioCryst hisse hedefini yükseltti

BioCryst’in 1Ç 2026 sonuçları: Satın alma masrafları %21’lik gelir artışını gölgeledi

BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates

ValuEngine Weekly Market Summary And Commentary

BioCryst, Ar-Ge başkanlığına Sandeep Menon’u atadı

BioCryst 2025 sunumu: 1 milyar dolarlık gelir yolu, Navenibart portföyü genişletiyor

BioCryst’in 4Ç 2025 sonuçları güçlü büyüme gösterdi, hisse düştü

RBC Capital, satın alma potansiyeli nedeniyle BioCryst hissesi notunu korudu

Micron and Intel among market cap stock movers on Monday

X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval